Current Affairs - Science - Discussion

Dr Reddy’s Laboratories received tentative approval from the United States Food and Drug Administration (USFDA) on 4th November 2026 for the first generic version of Lenacapavir, a long-acting injectable medicine used for HIV prevention. Lenacapavir is a first-in-class HIV-1 capsid inhibitor that helps prevent infection by targeting the virus at multiple stages of its lifecycle. It is administered twice a year and is used as Pre-exposure Prophylaxis (PrEP). The medicine is intended for distribution across 120 countries outside the United States under a voluntary licensing agreement with Gilead Sciences. Initial supplies are expected by the end of 2026.